Skip to content

CorMedix CRMD Free cash flow

Free cash flow at other companies

Pfizer logo
PfizerPFE
$2.18B+23.0%
Merck & Co. logo
Merck & Co.MRK
$2.93B+150%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$24.67M+26.5%
ITG
Integer HoldingsITGR
$737K-87.8%
IAR
Integra LifeSciencesIART
-$5.05M+87.4%
MiMedx Group logo
MiMedx GroupMDXG
$1.31M-73.4%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Calculated from CorMedix’s reported figures.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's free cash flow?
CorMedix (CRMD) reported free cash flow of $41.65M in Q1 2026.
How has CorMedix's free cash flow changed year-over-year?
CorMedix's free cash flow increased by 111.1% year-over-year, from $19.73M to $41.65M.
What is the long-term trend for CorMedix's free cash flow?
Over 4 years (2021 to 2025), CorMedix's free cash flow has grown at a 66.3% compound annual growth rate (CAGR), from -$22.58M to $172.79M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.